Compared to the SHP2-NC group, the SHP2-mimic group showed a significant reduction in tumor volume and weight; compared to the SHP2-NC+Sindilizumab group, the SHP2-mimic+Sindilizumab group had a significantly reduced tumor volume and weight. This evidence concerns the gene PTPN11 and neoplasm.